DOCSLIB.ORG

FIDA Quantity Limit List 508

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Elderplan 2016 Formulary Quantity Limits Drug Name Dose Form Quantity Limit Amount Quantity Limit Days acetaminophen-codeine #2 tab 300-15 ORAL TABLET 400 30 mg acetaminophen-codeine #3 tab 300-30 ORAL TABLET 400 30 mg acetaminophen-codeine #4 tab 300-60 ORAL TABLET 400 30 mg acetaminophen-codeine solution 120-12 SOLUTION 5000 30 mg/5ml acetaminophen-codeine tab 300-15 mg ORAL TABLET 400 30 acetaminophen-codeine tab 300-30 mg ORAL TABLET 400 30 acetaminophen-codeine tab 300-60 mg ORAL TABLET 400 30 acyclovir ointment 5 % TOPICAL OINTMENT 15 15 ADVAIR DISKUS AER POW BA 100­ DRY POWDER INHALER 60 30 50 MCG/DOSE ADVAIR DISKUS AER POW BA 250­ DRY POWDER INHALER 60 30 50 MCG/DOSE ADVAIR DISKUS AER POW BA 500­ DRY POWDER INHALER 60 30 50 MCG/DOSE ADVAIR HFA AEROSOL 115-21 METERED DOSE INHALER 12 30 MCG/ACT ADVAIR HFA AEROSOL 230-21 METERED DOSE INHALER 12 30 MCG/ACT ADVAIR HFA AEROSOL 45-21 METERED DOSE INHALER 12 30 MCG/ACT H8029_2016 Formulary ID: 16200 Version 7 Last Updated: 08/19/2015 Effective Date: 01/01/2016 *Brand name drugs are capitalized, generic drugs are lower-case and italicized. Elderplan 2016 Formulary Quantity Limits Drug Name Dose Form Quantity Limit Amount Quantity Limit Days ALINIA RECON SUSP 100 MG/5ML ORAL SUSPENSION 180 30 ALINIA TAB 500 MG ORAL TABLET 6 3 ALOXI 0.075 MG/1.5ML INJECTABLE SOLUTION 5 7 ALOXI SOLUTION 0.25 MG/5ML INJECTABLE SOLUTION 5 7 AMITIZA CAP 24 MCG ORAL CAPSULE 60 30 AMITIZA CAP 8 MCG ORAL CAPSULE 60 30 amlodipine besy-benazepril hcl cap 10­ ORAL CAPSULE 30 30 20 mg amlodipine besy-benazepril hcl cap 2.5­ ORAL CAPSULE 30 30 10 mg amlodipine besy-benazepril hcl cap 5-10 ORAL CAPSULE 30 30 mg amlodipine besy-benazepril hcl cap 5-20 ORAL CAPSULE 30 30 mg anastrozole tab 1 mg ORAL TABLET 30 30 ANDRODERM PATCH 24HR 2 TRANSDERMAL PATCH 30 30 MG/24HR ANDRODERM PATCH 24HR 4 TRANSDERMAL PATCH 30 30 MG/24HR aripiprazole tab 10 mg ORAL TABLET 30 30 aripiprazole tab 15 mg ORAL TABLET 30 30 aripiprazole tab 2 mg ORAL TABLET 30 30 aripiprazole tab 20 mg ORAL TABLET 30 30 aripiprazole tab 30 mg ORAL TABLET 30 30 H8029_2016 Formulary ID: 16200 Version 7 Last Updated: 08/19/2015 Effective Date: 01/01/2016 *Brand name drugs are capitalized, generic drugs are lower-case and italicized. Elderplan 2016 Formulary Quantity Limits Drug Name Dose Form Quantity Limit Amount Quantity Limit Days aripiprazole tab 5 mg ORAL TABLET 30 30 atorvastatin calcium tab 10 mg ORAL TABLET 30 30 atorvastatin calcium tab 20 mg ORAL TABLET 30 30 atorvastatin calcium tab 40 mg ORAL TABLET 30 30 atorvastatin calcium tab 80 mg ORAL TABLET 30 30 AVONEX KIT 30 MCG INJECTABLE SOLUTION 4 30 AVONEX PEN KIT 30 MCG/0.5ML INJECTABLE SOLUTION 4 30 AVONEX PREFILLED KIT 30 INJECTABLE SOLUTION 4 30 MCG/0.5ML azithromycin recon susp 100 mg/5ml SUSPENSION 120 30 azithromycin recon susp 200 mg/5ml SUSPENSION 120 30 budesonide suspension 0.25 mg/2ml SUSPENSION 240 30 budesonide suspension 0.5 mg/2ml SUSPENSION 120 30 butalbital-apap-caff-cod cap 50-325-40­ ORAL CAPSULE 370 30 30 mg CHANTIX CONTINUING MONTH ORAL TABLET 56 28 CHANTIX STARTING MONTH PAK ORAL TABLET 53 30 CHANTIX TAB 0.5 MG ORAL TABLET 11 30 CHANTIX TAB 1 MG ORAL TABLET 180 90 citalopram hydrobromide 10 mg ORAL TABLET 90 30 citalopram hydrobromide 40 mg ORAL TABLET 45 30 citalopram hydrobromide tab 10 mg ORAL TABLET 90 30 citalopram hydrobromide tab 20 mg ORAL TABLET 90 30 citalopram hydrobromide tab 40 mg ORAL TABLET 45 30 H8029_2016 Formulary ID: 16200 Version 7 Last Updated: 08/19/2015 Effective Date: 01/01/2016 *Brand name drugs are capitalized, generic drugs are lower-case and italicized. Elderplan 2016 Formulary Quantity Limits Drug Name Dose Form Quantity Limit Amount Quantity Limit Days DENAVIR CREAM 1 % TOPICAL CREAM 1.5 10 diazepam tab 10 mg ORAL TABLET 120 30 diazepam tab 2 mg ORAL TABLET 240 30 diazepam tab 5 mg ORAL TABLET 240 30 diclofenac gel 3% TOPICAL GEL 100 30 dronabinol cap 10 mg ORAL CAPSULE 60 30 dronabinol cap 2.5 mg ORAL CAPSULE 60 30 dronabinol cap 5 mg ORAL CAPSULE 60 30 duloxetine hcl cp dr part 20 mg ENTERIC COATED CAPSULE 60 30 duloxetine hcl cp dr part 30 mg ENTERIC COATED CAPSULE 60 30 duloxetine hcl cp dr part 60 mg ENTERIC COATED CAPSULE 60 30 ELIDEL CREAM 1 % TOPICAL CREAM 30 30 EMSAM PATCH 24HR 12 MG/24HR TRANSDERMAL PATCH 30 30 EMSAM PATCH 24HR 6 MG/24HR TRANSDERMAL PATCH 30 30 EMSAM PATCH 24HR 9 MG/24HR TRANSDERMAL PATCH 30 30 ENBREL KIT 25 MG INJECTABLE SOLUTION 16 30 ENBREL SOLN PRSYR 50 MG/ML PREFILLED SYRINGE 8 28 ENBREL SURECLICK SOLN A-INJ 50 PREFILLED SYRINGE 8 28 endocet tab 10-325 mg ORAL TABLET 370 30 endocet tab 5-325 mg ORAL TABLET 370 30 endocet tab 7.5-325 mg ORAL TABLET 370 30 enoxaparin sodium solution 100 mg/ml SOLUTION 20 10 enoxaparin sodium solution 120 SOLUTION 20 10 enoxaparin sodium solution 150 mg/ml SOLUTION 20 10 enoxaparin sodium solution 30 mg/0.3ml SOLUTION 20 10 H8029_2016 Formulary ID: 16200 Version 7 Last Updated: 08/19/2015 Effective Date: 01/01/2016 *Brand name drugs are capitalized, generic drugs are lower-case and italicized. Elderplan 2016 Formulary Quantity Limits Drug Name Dose Form Quantity Limit Amount Quantity Limit Days enoxaparin sodium solution 300 mg/3ml SOLUTION 20 10 enoxaparin sodium solution 40 mg/0.4ml SOLUTION 20 10 enoxaparin sodium solution 60 mg/0.6ml SOLUTION 20 10 enoxaparin sodium solution 80 mg/0.8ml SOLUTION 20 10 escitalopram oxalate solution 5 mg/5ml SOLUTION 600 30 escitalopram oxalate tab 10 mg ORAL TABLET 30 30 escitalopram oxalate tab 20 mg ORAL TABLET 30 30 escitalopram oxalate tab 5 mg ORAL TABLET 30 30 famciclovir tab 125 mg ORAL TABLET 21 10 famciclovir tab 250 mg ORAL TABLET 68 34 famciclovir tab 500 mg ORAL TABLET 21 7 fentanyl 100 mcg/hr TRANSDERMAL PATCH 10 30 fentanyl 12 mcg/hr TRANSDERMAL PATCH 10 30 fentanyl 25 mcg/hr TRANSDERMAL PATCH 10 30 fentanyl 75 mcg/hr TRANSDERMAL PATCH 10 30 fentanyl citrate loz handle 1200 mcg LOZENGE 120 30 fentanyl citrate loz handle 1600 mcg LOZENGE 120 30 fentanyl citrate loz handle 200 mcg LOZENGE 120 30 fentanyl citrate loz handle 400 mcg LOZENGE 120 30 fentanyl citrate loz handle 600 mcg LOZENGE 120 30 fentanyl citrate loz handle 800 mcg LOZENGE 120 30 fentanyl patch 72hr 100 mcg/hr TRANSDERMAL PATCH 10 30 fentanyl patch 72hr 12 mcg/hr TRANSDERMAL PATCH 10 30 fentanyl patch 72hr 25 mcg/hr TRANSDERMAL PATCH 10 30 FENTANYL PATCH 72HR 37.5 TRANSDERMAL PATCH 10 30 H8029_2016 Formulary ID: 16200 Version 7 Last Updated: 08/19/2015 Effective Date: 01/01/2016 *Brand name drugs are capitalized, generic drugs are lower-case and italicized. Elderplan 2016 Formulary Quantity Limits Drug Name Dose Form Quantity Limit Amount Quantity Limit Days fentanyl patch 72hr 50 mcg/hr TRANSDERMAL PATCH 10 30 FENTANYL PATCH 72HR TRANSDERMAL PATCH 10 30 fentanyl patch 72hr 75 mcg/hr TRANSDERMAL PATCH 10 30 FENTANYL PATCH 72HR 87.5 TRANSDERMAL PATCH 10 30 fluticasone propionate suspension 50 SUSPENSION 16 30 FORTEO SOLUTION 600 PREFILLED SYRINGE 2.4 28 FRAGMIN SOLUTION 10000 PREFILLED SYRINGE 9.5 5 FRAGMIN SOLUTION 12500 PREFILLED SYRINGE 2.5 5 FRAGMIN SOLUTION 15000 PREFILLED SYRINGE 3 5 FRAGMIN SOLUTION 18000 PREFILLED SYRINGE 3.6 5 FRAGMIN SOLUTION 2500 PREFILLED SYRINGE 2 5 FRAGMIN SOLUTION 25000 PREFILLED SYRINGE 19 5 FRAGMIN SOLUTION 5000 PREFILLED SYRINGE 3 5 UNIT/0.2ML FRAGMIN SOLUTION 7500 PREFILLED SYRINGE 1.5 5 FRAGMIN SOLUTION 95000 PREFILLED SYRINGE 19 5 UNIT/3.8ML gabapentin 100 mg ORAL CAPSULE 540 30 gabapentin 300 mg ORAL CAPSULE 360 30 gabapentin 400 mg ORAL CAPSULE 270 30 gabapentin cap 100 mg ORAL CAPSULE 540 30 gabapentin cap 300 mg ORAL CAPSULE 360 30 gabapentin cap 400 mg ORAL CAPSULE 270 30 H8029_2016 Formulary ID: 16200 Version 7 Last Updated: 08/19/2015 Effective Date: 01/01/2016 *Brand name drugs are capitalized, generic drugs are lower-case and italicized. Elderplan 2016 Formulary Quantity Limits Drug Name Dose Form Quantity Limit Amount Quantity Limit Days gabapentin tab 600 mg ORAL TABLET 120 30 gabapentin tab 800 mg ORAL TABLET 120 30 galantamine hydrobromide er cap EXTENDED RELEASE CAPSULE 90 30 er 24h 8 mg galantamine hydrobromide tab 12 ORAL TABLET 60 30 mg galantamine hydrobromide tab 4 ORAL TABLET 180 30 mg GAUZE PADS & DRESSINGS ­ NA 120 30 PADS 2 X 2 GLEEVEC TAB 100 MG ORAL TABLET 90 30 GLEEVEC TAB 400 MG ORAL TABLET 60 30 HUMIRA PEDIATRIC CROHNS PREFILLED SYRINGE 8 28 HUMIRA PEN PEN KIT 40 MG/0.8ML PREFILLED SYRINGE 8 28 HUMIRA PEN-CROHNS STARTER PREFILLED SYRINGE 8 28 HUMIRA PEN -PSORIASIS STARTER PREFILLED SYRINGE 8 28 HUMIRA PREF SY KT 10 MG/0.2ML PREFILLED SYRINGE 8 28 HUMIRA PREF SY KT 20 MG/0.4ML PREFILLED SYRINGE 8 28 HUMIRA PREF SY KT 40 MG/0.8ML PREFILLED SYRINGE 8 28 hydrocodone-acetaminophen solution SOLUTION 5500 30 2.5-108 mg/5ml hydrocodone-acetaminophen solution 5­ SOLUTION 5500 30 hydrocodone-acetaminophen solution SOLUTION 5500 30 7.5-325 mg/15ml hydrocodone-acetaminophen tab 10-325 ORAL TABLET 370 30 mg H8029_2016 Formulary ID: 16200 Version 7 Last Updated: 08/19/2015 Effective Date: 01/01/2016 *Brand name drugs are capitalized, generic drugs are lower-case and italicized.
Recommended publications
  • Formulation and Evaluation of Transdermal Patch and Gel of Nateglinide

    Formulation and Evaluation of Transdermal Patch and Gel of Nateglinide

    Human Journals Research Article September 2015 Vol.:4, Issue:2 © All rights are reserved by C. Aparna et al. Formulation and Evaluation of Transdermal Patch and Gel of Nateglinide Keywords: Nateglinide, transdermal patch and gel, HPMC, ethyl cellulose, carbopol, PVA, PVP ABSTRACT Anusha Gundeti, C. Aparna*, Dr. Prathima Srinivas The objective of the present work was to formulate Transdermal Drug Delivery systems of Nateglinide, an Department of Pharmaceutics, Sri Venkateshwara antidiabetic drug belonging to meglitinide class with a half life of 1.5 hrs. Transdermal patches containing nateglinide were College of Pharmacy, prepared by solvent casting method using the combinations Affiliated to Osmania University, of HPMC:EC, PVA:PVP, HPMC:Eudragit RS 100, Eudragit RL100:RS100 in different proportions and by incorporating Madhapur, Hyderabad, Telangana -500081, India. different permeation enhancers (polyethylene glycol 400, Su bmission: 7 September 2015 DMSO). The transdermal patches were evaluated for their physicochemical properties like thickness, weight variation, Accepted: 11 September 2015 folding endurance, percentage moisture absorption, percentage Published: 25 September 2015 moisture loss, in-vitro diffusion studies & ex-vivo permeation studies. Transdermal Gel was formulated using HPMC, carbopol 934, carbopol 940 and methyl cellulose. Gels were evaluated for homogeneity, pH, viscosity, drug content, in-vitro diffusion studies & ex-vivo permeation studies. By comparing the drug release F5 (HPMC:EC) formulation was selected as optimized formulation as it could sustain the drug release for 12 hrs i.e. 99.2% when compared to gel. Stability studies were www.ijppr.humanjournals.com carried out according to ICH guidelines and the patches maintained integrity and good physicochemical properties during the study period.
  • Inhalation Devices: Various Forms of Administration for Therapeutic Optimization

    Inhalation Devices: Various Forms of Administration for Therapeutic Optimization

    vv ISSN: 2640-8082 DOI: https://dx.doi.org/10.17352/oja CLINICAL GROUP Renata Cristina de Angelo Calsaverini Leal* Review Article Santa Fé do Sul Foundation of Education and Culture, Brazil Inhalation Devices: Various forms Dates: Received: 31 May, 2017; Accepted: 26 June, of administration for Therapeutic 2017; Published: 27 June, 2017 *Corresponding author: Renata Cristina de Angelo Optimization Calsaverini Leal, Santa Fé do Sul Foundation of Education and Culture, Brazil, Tel: 55 (17) 3272-2769, E-mail: Keywords: Inhalation; Aerosol; Nebulizer Summary https://www.peertechz.com Introduction: Aerosol therapy consists of spraying liquid particles suspended for therapeutic purposes in the respiratory tract. With direct absorption and deposition at the lung level, avoiding side effects and presenting fast response time. Several factors infl uence the drug action, such as size, particle movement, ventilatory fl ow, pulmonary expansion, anatomy, respiratory mechanics and the nebulizer and patient interface. The therapeutic optimization depends on the type of nebulizer differentiating itself by the physical principle that generates the mist. Objectives: Check advantages and disadvantages of different inhalation devices. Methodology. This is a review of the PubMed database using descriptors: ultrasonic and jet nebulizer, aerosol deposition in the lung, metered dose inhaler and dry, inhaler therapy. Results: Different devices are mentioned in the literature: pneumatic and ultrasonic nebulizers (administering solutions), metered pressurized inhalers - pMDI used with or without expander chamber (administering suspensions) and dry powder inhalers - DPI (administering powder). Discussion and Conclusion: The US has advantages: quiet, does not require coordinating abilities, without propellant gases and quick nebulization with small amount of solution. Disadvantages: change in the active principle of thermosensitive drugs, deposition in the oropharynx and VAI of 2% of inhaled particles.
  • Inhaled Steroids in Asthma a Patient's Guide

    Inhaled Steroids in Asthma a Patient's Guide

    I I v v v v d v v Patient advice and liaison service (PALS) Actions r v If you have a compliment, complaint or It is sensible to ensure you make the r concern please contact our PALS team on following steps now you have a new r 020 7288 5551 or inhaler d [email protected] d d Pick up our guide on inhalers and If you need a large print, audio or spacers to complement this leaflet translated copy of this leaflet please Inhaled Steroids in Agree on a personalised asthma contact us on 020 7288 3182. We will try plan (this is done with your doctor or our best to meet your needs. Asthma nurse and usually written down for future reference) Remember to take your medicines A patient’s guide as advised Should your inhalers fail to relieve your symptoms, go straight to Accident and Emergency Need Help? Whittington Paediatric Asthma Nurse Tel: 020 7288 5527 Whittington Health Community Nurse Magdala Avenue Islington 020 3316 1950 (8am-6pm) London N19 5NF Haringey 020 8887 3301 (9am – 5pm) Phone: 020 7272 3070 www.whittington.nhs.uk Asthma UK 0300 222 5800 Date published: 25/09/2018 www.asthma.org.uk Review date: 25/09/2020 Ref: C&YP/Paed/ISA/03 © Whittington Health Please recycle Tel: 020 7272 3070 Asthma There are many types of preventer Side Effects Asthma is a common condition affecting inhaler. There are simple steroids like Parents worry about children and young the airway. Usually a trigger (such as dust beclomethasone, and then there are also adults taking inhaled steroids because of or pollen) irritates the airways which combined inhalers, called seretide or side effects they’ve heard about.
  • Member List 2016

    Member List 2016

    To help make the use of prescription drugs safer and more affordable, our plan is now using a Drug Quantity Management program. That is, for certain medications, you can receive an amount to last you a certain number of days. This gives you the right amount to take the daily dose considered safe and effective, according to the recommendations of the U.S. Food and Drug Administration (FDA). Based on the FDA’s guidelines and other medical information, our plan developed this program together with Express Scripts, the company chosen to manage our prescription drug benefit. The following limits are based on a 30-day supply. If your plan allows for additional days supply, your limits may be higher. For instance, you may be able to get a 90-day supply of your medication through mail order service. Your doctor could also request a prior authorization. If this request is approved, a prior authorization would let you receive more than the recommended quantity. Drug Target Maximum Quantity ABSTRAL 100 MCG TAB SUBLINGUAL 90 units per 30 days ABSTRAL 200 MCG TAB SUBLINGUAL 90 units per 30 days ABSTRAL 300 MCG TAB SUBLINGUAL 90 units per 30 days ABSTRAL 400 MCG TAB SUBLINGUAL 90 units per 30 days ABSTRAL 600 MCG TAB SUBLINGUAL 90 units per 30 days ABSTRAL 800 MCG TAB SUBLINGUAL 90 units per 30 days ACTIQ 1,200 MCG LOZENGE 90 units per 30 days ACTIQ 1,600 MCG LOZENGE 90 units per 30 days ACTIQ 200 MCG LOZENGE 90 units per 30 days ACTIQ 400 MCG LOZENGE 90 units per 30 days ACTIQ 600 MCG LOZENGE 90 units per 30 days ACTIQ 800 MCG LOZENGE 90 units per
  • Drugs That Are Not Covered

    Drugs That Are Not Covered

    Drugs that are Not Covered* Current 10/1/21 In addition to this list, newly marketed prescription medications may not be covered until the Pharmacy & Therapeutics Committee has had an opportunity to review the medication, to determine whether the medication will be covered and if so, which tier will apply based on safety, efficacy and the availability of other products within that class of medications. The current list of newly marketed drugs can be found on our New to Market Drug list. Abilify tablets albuterol HFA inhalers (authorized Apexicon E cream Abilify MyCite tablets generics for ProAir, Proventil, Ventolin Apidra vials Absorica capsules HFA inhalers) Apidra SoloStar injection Absorica LD capsules Aldactone tablets Aplenzin tablets Abstral sublingual tablets Aldara cream Apriso capsules Acanya gel and pump gel Alkindi sprinkle capsules Arava tablets Accupril tablets Allegra Children’s Allergy ODT Arazlo lotion acetaminophen 320.5 mg/caffeine 30 Allegra ODT, suspension and tablets Arestin microspheres mg/dihydrocodeine 16 mg Alltizal tablets Aricept tablets capsulesAciphex tablets alogliptin (authorized generic for Aricept ODT Aciphex Sprinkle capsules Nesina) Arimidex tablets Acticlate tablets alogliptin/metformin tablets (authorized Arixtra injection Active-Prep kits generic for Kazano) ArmonAir Digihaler inhaler Activella tablets alogliptin/pioglitazone (authorized ArmonAir Respiclick inhaler Actonel tablets generic for Oseni) Aromasin tablets Actoplus Met tablets Alphagan P 0.1% eye drops Arthrotec 50 and 75 tablets Actos
  • An Archetype Swing in Transdermal Drug Delivery

    An Archetype Swing in Transdermal Drug Delivery

    Indo American Journal of Pharmaceutical Research, 2017 ISSN NO: 2231-6876 A COMPREHENSIVE REVIEW ON MICRONEEDLES - AN ARCHETYPE SWING IN TRANSDERMAL DRUG DELIVERY G. Ravi*, N. Vishal Gupta, M. P. Gowrav Department of Pharmaceutics, JSS College of Pharmacy, JSS University, Shri Shivarathreeshwara Nagara, Mysuru, Karnataka, India. ARTICLE INFO ABSTRACT Article history Transdermal drug delivery is the non-invasive delivery of medications through the skin Received 23/12/2016 surface into the systemic circulation. The advantage of transdermal drug delivery system is Available online that it is painless technique of administration of drugs. The advantage of transdermal drug 31/01/2017 delivery system is that it is painless technique of administration of drugs. Transdermal drug delivery system can improve the therapeutic efficacy and safety of the drugs because drug Keywords delivered through the skin at a predetermined and controlled rate. Due to the various Microneedles, biomedical benefits, it has attracted many researches. The barrier nature of stratumcorneum Hypodermic Needles, poses a danger to the drug delivery. By using microneedles, a pathway into the human body Transdermal, can be recognized which allow transportation of macromolecular drugs such as insulin or Stratumcorneum, vaccine. These microneedles only penetrate outer layers of the skin, exterior sufficient not to Patch. reach the nerve receptors of the deeper skin. Thus the microneedles supplement is supposed painless and reduces the infection and injuries. Researches from the past few years showed that microneedles have emerged as a novel carrier and considered to be effective for safe and improved delivery of the different drugs. Microneedles development is created a new pathway in the drug delivery field.
  • L092 Session: L168 Thoracic Epidural Analgesia in the Re

    L092 Session: L168 Thoracic Epidural Analgesia in the Re

    Session: L092 Session: L168 Thoracic Epidural Analgesia in the Recently Anticoagulated Patient: Is This a Good Idea? Anuj Malhotra, M.D. Icahn School of Medicine at Mount Sinai, New York, NY Disclosures: This presenter has no financial relationships with commercial interests Stem Case and Key Questions Content A 52 year old male presents for open resection for colon cancer. He has had multiple prior abdominal surgeries and the planned approach is a supraumbilical midline incision that will cover the T6-T10 dermatomes. The patient is obese and has a history of COPD. Vitals: HR 70, BP 126/68, O2 sat 95% on RA, Ht 6'0", Wt 285 lbs 1) What surgical features and patient factors make this patient a good candidate for a thoracic epidural? 2) What level should this block be placed at? Should it be placed paramedian or midline? What should be infused? 3) Does it matter if the epidural is activated before surgery (pre-emptive analgesia) or after? What are the pros and cons of early dosing? The patient also has chronic abdominal pain treated with methadone 10 mg three times daily and oxycodone 5-10 mg four times daily. He is very concerned about difficulty with extubation, postoperative pain, and ileus. Medications: Methadone 10 mg tid, oxycodone 5-10 mg q 6 hrs prn, albuterol inhaler prn, fluticasone/salmeterol inhaler bid, metoprolol XL 50 mg daily ECG: irregularly irregular @ 70 bpm, QTc 440 ms 4) What patient characteristics suggest the need for postoperative pain control? Will thoracic epidural analgesia decrease ileus? Will it shorten duration of postoperative mechanical ventilation? 5) Does thoracic epidural analgesia affect long-term outcomes such as mortality or chronic postoperative pain? 6) Should his methadone be continued perioperatively if he has a neuraxial block for pain control? Upon reviewing the ECG and questioning the patient further, he reports a recent diagnosis of atrial fibrillation for which he takes dabigatran 150 mg bid for stroke prevention.
  • Transdermal Nicotine Maintenance Attenuates the Subjective And

    Transdermal Nicotine Maintenance Attenuates the Subjective And

    Neuropsychopharmacology (2004) 29, 991–1003 & 2004 Nature Publishing Group All rights reserved 0893-133X/04 $25.00 www.neuropsychopharmacology.org Transdermal Nicotine Maintenance Attenuates the Subjective and Reinforcing Effects of Intravenous Nicotine, but not Cocaine or Caffeine, in Cigarette-Smoking Stimulant Abusers 1 1 ,1,2 Bai-Fang X Sobel , Stacey C Sigmon and Roland R Griffiths* 1Department of Psychiatry and Behavioral Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA; 2Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA The effects of transdermal nicotine maintenance on the subjective, reinforcing, and cardiovascular effects of intravenously administered cocaine, caffeine, and nicotine were examined using double-blind procedures in nine volunteers with histories of using tobacco, caffeine, and cocaine. Each participant was exposed to two chronic drug maintenance phases (21 mg/day nicotine transdermal patch and placebo transdermal patch). Within each drug phase, the participant received intravenous injections of placebo, cocaine (15 and 30 mg/70 kg), caffeine (200 and 400 mg/70 kg), and nicotine (1.0 and 2.0 mg/70 kg) in mixed order across days. Subjective and cardiovascular data were collected before and repeatedly after drug or placebo injection. Reinforcing effects were also assessed after each injection with a Drug vs Money Multiple-Choice Form. Intravenous cocaine produced robust dose-related increases in subjective and reinforcing effects; these effects were not altered by nicotine maintenance. Intravenous caffeine produced elevations on several subjective ratings; nicotine maintenance did not affect these ratings. Under the placebo maintenance condition, intravenous nicotine produced robust dose-related subjective effects, with maximal increases similar to the high dose of cocaine; nicotine maintenance significantly decreased the subjective and reinforcing effects of intravenous nicotine.
  • A Brief Review on Transdermal Patches

    A Brief Review on Transdermal Patches

    Organic and Medicinal Chemistry International Journal ISSN 2474-7610 Review Article Organic & Medicinal Chem IJ Volume 7 Issue 2 - June 2018 Copyright © All rights are reserved by Nidhi Sharma DOI: 10.19080/OMCIJ.2018.07.555707 A Brief Review on Transdermal Patches Nidhi Sharma* HIMT College of Pharmacy, Greater Noida, India Submission: May 12, 2018; Published: June 05, 2018 *Corresponding author: Nidhi Sharma, HIMT College of Pharmacy, Greater Noida, India, Email: Abstract healingTransdermal to an injured drug area delivery of the system body. was An presentedadvantage toof overcome a transdermal the difficulties drug delivery of drug route delivery over especiallyother types oral of route. delivery A transdermal system such patch as oral, is a topical,medicated i.v., adhesive i.m., etc. ispatch that that the patchis placed provides on the askin controlled to deliver release a specific of the dose medication of medication into the through patient, the usually skin and through into the either bloodstream. a porous It membrane promotes covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive. The main disadvantage to transdermal delivery systems stems from the fact that the skin is a very effective barrier, as a result, only medications whose molecules are small can easily penetrate the skin, so it can be delivered by this method. This review article describes the overall introduction of transdermal patches including type of transdermal patches, method of preparation of transdermal
  • Medication Administration

    Medication Administration

    MEDICATION ADMINISTRATION GENERAL CONSIDERATIONS A. Before administering any medication, the EMT should know: 1. What is the medication being used? 2. Does the patient have an allergy to this medication? 3. What is the safe and effective dose? 4. What is the correct administration route? 5. What are the indications? (Why are you using is?) 6. What are the contraindications? (Why or when would you NOT use this medication?) 7. What are the expected effects? 8. What are the adverse effects / side effects? 9. Is the medication expired? B. The “Six Rights” of medication administration: 1. Right patient – is the medication indicated for this patient; no contraindications; no allergies 2. Right drug – the correct name (trade name vs. generic name); correct concentration 3. Right dose 4. Right route 5. Right time – slow IVP vs. rapid IVP 6. Right documentation C. Correct documentation of medications administered and/or IV/IO placement will include: 1. Time of medication administration; IV/IO placement 2. Route of administration 3. Size of catheter (IV/IO) 4. Site location for IV/IO and SQ, IM medication (include unsuccessful IV/IO attempt locations) 5. Dose or volume infused 6. Time of infusion as indicated (e.g., rapid IVP, infused over 10 minutes, etc.) 7. Name of EMT responsible 8. Any complications and steps made to correct 9. Patient’s response to treatment D. Use of a medication simply because it is in the protocol is not an acceptable standard of medical care. When there are questions about medication administration, consult medical control. ORAL ADMINSTRATION To administer an oral (PO) medication ensure that the patient has an intact gag reflex and place the patient in a seated or semi-seated position.
  • A Guide to Aerosol Delivery Devices for Respiratory Therapists 4Th Edition

    A Guide to Aerosol Delivery Devices for Respiratory Therapists 4Th Edition

    A Guide To Aerosol Delivery Devices for Respiratory Therapists 4th Edition Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Dave Burnett, PhD, RRT, AE-C Shawna Strickland, PhD, RRT-NPS, RRT-ACCS, AE-C, FAARC Timothy R. Myers, MBA, RRT-NPS, FAARC Platinum Sponsor Copyright ©2017 by the American Association for Respiratory Care A Guide to Aerosol Delivery Devices for Respiratory Therapists, 4th Edition Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Dave Burnett, PhD, RRT, AE-C Shawna Strickland, PhD, RRT-NPS, RRT-ACCS, AE-C, FAARC Timothy R. Myers, MBA, RRT-NPS, FAARC With a Foreword by Timothy R. Myers, MBA, RRT-NPS, FAARC Chief Business Officer American Association for Respiratory Care DISCLOSURE Douglas S. Gardenhire, EdD, RRT-NPS, FAARC has served as a consultant for the following companies: Westmed, Inc. and Boehringer Ingelheim. Produced by the American Association for Respiratory Care 2 A Guide to Aerosol Delivery Devices for Respiratory Therapists, 4th Edition American Association for Respiratory Care, © 2017 Foreward Aerosol therapy is considered to be one of the corner- any) benefit from their prescribed metered-dose inhalers, stones of respiratory therapy that exemplifies the nuances dry-powder inhalers, and nebulizers simply because they are of both the art and science of 21st century medicine. As not adequately trained or evaluated on their proper use. respiratory therapists are the only health care providers The combination of the right medication and the most who receive extensive formal education and who are tested optimal delivery device with the patient’s cognitive and for competency in aerosol therapy, the ability to manage physical abilities is the critical juncture where science inter- patients with both acute and chronic respiratory disease as sects with art.
  • Therapeutic Aerosols 2-Drugs Available by the Inhaled Route

    Therapeutic Aerosols 2-Drugs Available by the Inhaled Route

    Thorax 1984;39:1-7 Thorax: first published as 10.1136/thx.39.1.1 on 1 January 1984. Downloaded from Editorial Therapeutic aerosols 2-Drugs available by the inhaled route Inhalation treatment can be said to have stood the umes have been written about them and their test of time, since records can be traced back several administration.3 Reiterating most of this would be thousand years. In ancient Greece, Hippocrates like taking "coals to Newcastle" for the readers of employed the inhalation of vapours distilled in a pot, Thorax and therefore only selected aspects will be the lid of which was pierced by a reed;' sulphur and mentioned. arsenic were said to have been used. The patient The naturally occurring catecholamine adrenaline breathing these hot vapours needed protection with was the earliest of these drugs to be given by inhala- moistened sponges to avoid scalding. The popularity tion,4 followed by isoprenaline (isopropylnoradren- of these inhalation procedures has waxed and aline) in about 1960. Since adrenaline, however, waned, as Miller' writes-at times they have been stimulates both a and ,3 receptors in the heart and over praised and unwisely used, and at other times periphery and isoprenaline stimulates 8,/ and (2 unreasonably condemned and virtually abandoned. receptors, both drugs may give rise to undesirable The latter phrase still applies to some extent today. cardiovascular side effects such as tachycardia or Until the middle of the present century, inhalation arrhythmias. Adrenaline, whether given by injection treatment with volatile aromatic substances with a or by inhalation, is now little used in Britain.